WealthStone’s Biogen BIIB Stock Holding History

WealthStone’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$228K	Buy	+818	New	+$221K	0.08%	220
2019 Q3	–	Sell	-3	Closed	-$701	–	123
2019 Q2	$701	Buy	+3	New	+$693	﹤0.01%	750

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WealthStone's BIIB Position: Q1 2021 in Review

WealthStone opened a new position in Biogen (BIIB) in Q1 2021: 818 shares worth $228K. The stake represents 0.08% of the portfolio and ranks #220 among its holdings. This is a return to the name: WealthStone previously reported a position in BIIB as recently as Q2 2019.

WealthStone first reported a position in BIIB in Q2 2019 and has held it in 2 quarters since. 1,093 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

WealthStone held 818 shares of Biogen worth $228K as of Q1 2021.
Biogen was a new WealthStone position in Q1 2021.
Biogen made up 0.08% of WealthStone's portfolio in Q1 2021, its #220 holding.
WealthStone first reported a position in Biogen in Q2 2019 and has held it in 2 quarters since.
1,093 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on WealthStone's 13F filing for Q1 2021, filed 13 May 2021.